Skip to content

Finger Prick blood collection validation studies

Finger Prick blood collection validation studies - Finger Prick blood collection validation studies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51204
Enrollment
360
Registered
2021-06-18
Start date
2021-09-13
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19 serology general clinical chemistry HbA1C IVD Diagnostic tests: PSA

Interventions

None listed

Sponsors

Antoni van Leeuwenhoek Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients: 120x PSA requirest at blood collection facility 120x HbA1c request at blood collection facility Healthy volunteers: 120X Proven Covid-19 infection health care professional 120X Partner of NKI patient (without Cancer)

Exclusion criteria

Exclusion criteria: N.A.

Design outcomes

Primary

MeasureTime frame
Primary Objective: - To determine whether the finger prick blood collection system procedure can reliably replace venepuncture blood collection for the PSA, Covid-19 serology, HbA1c and routine clinical chemistry testing. Validation requirements: - Correlation coefficient (Spearmans) of finger prick with venipuncture serum is > 0,90. - Regression analysis: 95% CI of slope includes 1.00 - Less than 5% outliers (recovery 130%)

Secondary

MeasureTime frame
- Finger prick blood collection procedure performed by patients or healthy volunteers is feasible: > 80% of finger prick blood collection procedures performed results in a suitable sample for analysis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 1, 2026